Showing 8201-8210 of 9793 results for "".
- DuPont to Launch GENENCARE® OSMS PRO for Pollution Protectionhttps://practicaldermatology.com/news/dupont-to-launch-genencare-osms-pro-for-pollution-protection/2457858/DuPont Industrial Biosciences will soon launch Genencare® OSMS PRO, a new product for the personal care industry that helps protect skin from pollution, while contributing to the natural cellular defense process.
- Vit D Levels Elevated in Acnehttps://practicaldermatology.com/news/vit-d-levels-higher-in-acne/2457867/Levels of vitamin D are higher in acne patients, compared to age/sex matched controls. Researchers found a significant inverse relation between level of 25 hydroxy vitamin D and severity of acne vulgaris before treatment, according to a study in Journal of Cosmetic Dermatology.
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- ISDIN AGE Contour Launches for Face and Neckhttps://practicaldermatology.com/news/isdin-age-contour-launches-for-face-and-neck/2457869/ISDIN has launched ISDIN AGE Contour, a triple action face and neck cream packed with ingredients to fight three key aspects of skin aging. Formulated with a tripeptide complex con
- New DermTech Research Validates Gene Expression Against High-Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanomahttps://practicaldermatology.com/news/new-dermtech-research-validates-gene-expression-against-high-risk-dna-mutations-providing-objective-information-for-the-diagnosis-of-melanoma/2457871/DermTech, Inc. presented a late breaking abstract—“Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS, and TERT) in Cutaneous Melanoma” —at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Di
- Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis/2457873/Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediat
- Meet the Newest AAD Officers and Board Membershttps://practicaldermatology.com/news/meet-the-newest-aad-officers-and-board-members/2457876/Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an ass
- Exciplex Phototherapy Device Debuts at AAD 2018https://practicaldermatology.com/news/exciplex-phototherapy-device-debuts-at-aad-2018/2457877/Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during t
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal
- Biofrontera Rings Nasdaq Market Closing Bellhttps://practicaldermatology.com/news/biofrontera-rings-nasdaq-closing-bell/2457881/Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell